Clinical Trial Update: A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) [Phase 1, Phase 2]

View source ↗

Summary

This update describes BEAM-201, a study in relapsed/refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma, in Phase 1/2 and currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoblastic Leukemia
• T-cell Acute Lymphoblastic Leukemia
• T-cell Lymphoblastic Lymphoma

Drugs mentioned

• BEAM-201

Snippet

Sponsor: Beam Therapeutics Inc. | Conditions: Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING